New order under mtec prototype (mtec-22-02-mpai). The project title is: identifying a novel neuroprotective nmda antagonist for acute traumatic brain injury.
Active Awarded Last action
- Contract number
- W81XWH2290020
- Awardee
-
Medical Technology Enterprise Consortium UEI RTGVVL7F6J11
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $3,029,760
Award facts
- Contract value 100% obligated
- $3,029,760.34 Current and potential, with all options
- Completion date 99% complete
- Current and potential, with all options
- Funding agency
- Medical Command Department of the Army, Department of Defense
- NAICS code
- Not on record
- Set-aside
- No set-aside
- Competition
- Competed Program Solicitation
- Pricing
- Other
- Place of performance
- Summerville, SC 29486, USA
- Primary consortia member
- Eumentis Therapeutics Inc.
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $1,162,369 | |
| Original award | $1,867,392 |
About this award
This contract award to the Medical Technology Enterprise Consortium (MTEC), a nonprofit organization that serves as a medical technology accelerator for the Department of Defense, is for a new order under the MTEC Prototype (MTEC-22-02-MPAI) project titled "Identifying a Novel Neuroprotective NMDA Antagonist for Acute Traumatic Brain Injury." The contract has a ceiling value of $3,029,760.34 and a completion date of October 31, 2026. It is an Other Transaction Order contract, which allows for flexible, non-traditional contracting methods. This award is not associated with a set-aside designation. MTEC has a proven track record of delivering over $500 million in prototypes, research and development, data analytics, and medical countermeasures to support federal agencies' medical technology priorities and readiness missions, including for the Army Medical Command, Defense Health Agency, and Navy Bureau of Medicine and Surgery. The consortium's work spans a wide range of medical research and development projects, including those focused on combat wound treatment, brain health technologies, and advanced biomedical product development for naval operations.
Quick answers
Who was awarded contract W81XWH2290020?
W81XWH2290020 was awarded to Medical Technology Enterprise Consortium by Defense Health Agency (Department of Defense) on September 14, 2022.
How much is contract W81XWH2290020 worth?
The government has obligated $3,029,760 on W81XWH2290020.
Which agency awarded contract W81XWH2290020?
Defense Health Agency (Department of Defense) awarded W81XWH2290020, with funding from Medical Command (Department of the Army).
Is contract W81XWH2290020 an order under another contract?
Yes. W81XWH2290020 is an other transaction order under W81XWH1590001, an other transaction IDV.
Was contract W81XWH2290020 competed?
The extent of competition for W81XWH2290020 was competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award